| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and lowers the price ...
																	
																	Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservatio...
																	
																	https://scholarrock.com/our-company/newsroom/update-on-third-party-manufacturing-site/
																	
																	
																	B of A Securities analyst Tazeen Ahmad initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Buy rating and announ...
																	U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceutical...